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Ghrelin, a 28-amino acid peptide gut hormone, occurs 
in acylated (AG) and unacylated (UAG) variants. AG 
is a GH secretagogue as well as being orexigenic and 
diabetogenic, acting via the growth hormone secreta-
gogue receptor (GHSR1a) in the hypothalamus and pitu-
itary. UAG counteracts these metabolic effects through 
unknown mechanisms. While screening for potential UAG 
receptor(s) we discovered previously uncharacterised 
interactions of AG and UAG with five cell membrane 
proteins (MPs), three of which are known to modulate me-
tabolism. Here, we studied if two of these MPs (MP1  & 
2) could modulate GHSR1a signalling by expressing their 
transgenes in HEK293 cells. As GHSR1a is coupled with 
calcium signalling via Gq proteins, aequorin luminescence 
was used to evaluate Ca2+ influx into the cells. Transfected 
cells were treated with either AG, UAG, or soluble parts of 
the MPs, or combinations thereof.
MP2 markedly enhanced the efficacy (~5.5-fold), but not the 
potency, of AG-induced Ca2+ influx, whereas MP1 had no ef-
fect on Ca2+ influx. Neither MP1 nor MP2 overexpression 
altered cellular GHSR1a levels. In the absence of GHSR1a, 
MP2 was unable to stimulate an AG-induced Ca2+ influx. 
UAG treatment (100nM) had no effect on GHSR1a-mediated 
Ca2+ influx in the presence or absence of MP2. MP2 is post-
translationally modified and we suspected this to be im-
portant for its activity. However, removal or blockade of 
these modifications had no effect on the ability of MP2 to 
enhance GHSR1a signalling. Moreover, incubating the cells 
with soluble ectodomain of MP2 did not alter its effect on 
GHSR1a signalling. Nevertheless, induction of ectodomain 
shedding with PMA (0.4-1µM) dose-dependently reduced 
the AG-induced Ca2+ response to 0.5-0.2 of control levels 
(DMSO) in MP2-GHSR1a co-transfected cells. Unlike 
MP2, which has a transmembrane and intracellular do-
main, MP1 is attached to the plasma membrane via a 
glycosylphosphatidylinositol (GPI) anchor and lacks an 
intracellular domain. Since MP1 is otherwise structurally 
similar to MP2, we suspected that the intracellular domain 
of MP2 may be important for its function. Therefore, we 
expressed chimeras of MP2 and MP1 in which the GPI 
linkage site and the transmembrane/intracellular domains 
were exchanged. The MP2 ectodomain with a GPI-anchor 
had similar stimulatory effects on GHSR1a signalling as 
full-length MP2, whereas the MP1 ectodomain with MP2 
transmembrane and intracellular domain only enhanced 
GHSR1a signalling by approximately 3-fold.
In conclusion, we have identified a membrane protein as 
a novel component of the ghrelin signalling pathway that 
markedly enhances the response of the ghrelin receptor to 
AG. Our current data suggest its ectodomain is important 
in mediating this effect. Studies are ongoing to fully delin-
eate the mode of interaction and to determine the role of 
MP2 in ghrelin signalling in vivo.
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BACKGROUND: The relationship between health status, 
defined by frailty and comorbidities, and serum T levels 
has been widely demonstrated in general population, while 
only one previous retrospective study has explored it in 
HIV-infected men1.
AIM: To investigate the association between frailty and go-
nadal status by assessing serum total T (TT) with Liquid 
Chromatography tandem Mass Spectrometry (LC-MS/MS) 
in a cohort of HIV-infected men.
METHODS: Prospective, cross-sectional, observational 
study on HIV-infected men (age <50  years) with on-
going Highly Active Antiretroviral Therapy. Serum TT 
was assessed by the gold standard ID-LC-MS/MS. Sex 
hormone-binding globulin (SHBG) was measured by chem-
iluminescent immunoassay. Calculated free T (cFT) was 
obtained by Vermeulen equation. Multimorbidity was de-
fined as at least 3 comorbid conditions, including: hyperten-
sion, diabetes, cardiovascular disease, chronic obstructive 
pulmonary disease, chronic kidney disease, osteoporosis, 
chronic viral hepatitis and cancers. Frailty was calculated 
through the validated 37-item frailty index (FI)2. Patients 
with FI>0.21 were considered frail. Statistical ana-
lysis: Mann-Whitney U test was used to compare contin-
uous variables. Correlations were performed using linear 
regression models.
RESULTS: 315 consecutive HIV-infected men were 
enrolled (mean age 45.3±5.3  years; average duration of 
HIV-infection 16.3±8.8 years). 128 patients (40.5%) were co-
morbid and 207 (64.9%) were frail. Either cFT (p=0.001) or 
TT (p<0.001) were lower in comorbid patients than others. 
FT was inversely related to the number of comorbidities 
(p<0.001, R2=0.045). Accordingly, cFT (p=0.003) and 
TT (p<0.001) were significantly lower in frail patients. 
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Frailty score was inversely correlated with cFT (p<0.001, 
R2=0.058), TT (p=0.041, R2=0.014) and SHBG (p=0.003, 
R2=0.029). However, after adjustment for age and duration 
of HIV-infection, cFT, TT and SHBG were excluded from 
the regression model.
CONCLUSIONS: Low cFT and TT levels are associated 
with multimorbidity and poor health status in HIV infected 
men. The bidirectional nature of this relationship leads to 
the figuration of an intriguing vicious circle where T de-
ficiency triggers the onset of comorbidities or, vice versa, 
poor health status induces hypogonadism. At the same 
time, notwithstanding the inverse relation between FT and 
frailty, it seems that other stronger predictive factors, and 
in particular the duration of infection, are involved in de-
termining the health outcome in this clinical setting.
REFERENCES
1Rochira V et al. Low testosterone is associated with poor 
health status in men with human immunodeficiency 
virus infection: a retrospective study. Andrology. 2015 
Mar;3(2):298-308.
2Guaraldi et  al. A  frailty index predicts survival and in-
cident multimorbidity independent of markers of HIV di-
sease severity. AIDS. 2015 Aug 24;29(13):1633-41.
Adrenal
ADRENAL CASE REPORTS I
Treatment-Resistant Hypertension in a Post-
Transplant Patient with Cystic Fibrosis: A Rare Case 
of Pheochromocytoma
David Joseph Tansey, MB BCh BAO (Hons) MRCPI1,  
Mensud Hatunic, MB BCH MD2, John Conneely, MB BCH 
MRCSI1, Michelle Murray, MB BCH BAO MRCPI1.
1Mater Misericordiae University Hospital, Dublin 7, Ireland, 
2Mater Misericordiae University Hospital, Dublin 7, Ireland.
SAT-209
Background: Pheochromocytoma is a rare catecholamine-
producing tumor with an estimated incidence of less than 
0.1% in the global population. We present the case of a pheo-
chromocytoma in a 25-year-old man with a background his-
tory of a double-lung transplant for Cystic Fibrosis, carried 
out 5 years earlier. Clinical Case: A 25 year old, with a 
background history of Cystic Fibrosis and a Double Lung 
transplant in 2012 presented to the emergency depart-
ment with crampy abdominal pain, nausea and vomiting. 
He was diagnosed with Distal Intestinal Obstruction syn-
drome (DIOS) for which he was admitted for rehydration 
and laxatives. Contrast-enhanced computed tomography 
(CT) imaging of the abdomen and pelvis which showed 
a 3.4 cm right adrenal lesion, which was confirmed by a 
subsequent MRI Adrenals and an Endocrinology review 
was requested. On review, the patient was noted to be hy-
pertensive with a blood pressure averaging 170/90 despite 
treatment with 3 different anti-hypertensive medications 
- namely amlodipine, telmisartan and doxazosin. On re-
view of his medical notes, it was clear that he had been 
persistently hypertensive over the last 3  years. On fur-
ther questioning, he noted increasingly frequent sweating 
episodes over the last number of months but denied any 
palpitations, headache or back pain. Laboratory analysis 
showed an elevated plasma normetanephrines (NMN) of 
3167 pmol/L (182-867) as well as elevated metanephrines 
(MN) of 793 pmol/L (61-377) and high 3-MT of 257 
pmol/L (<185). His MIBG scan showed only a mild in-
crease in the uptake of tracer to the right adrenal gland 
compared to the left. The case was discussed at a multi-
disciplinary meeting and given the suggestive laboratory 
and radiologic findings, a presumptive diagnosis of phe-
ochromocytoma was made. After controlling blood pres-
sure with an alpha-blocker and beta-blocker for a week, 
the patient was hydrated and scheduled for an elective 
right adrenalectomy. The histopathology of the excised 
adrenal gland was consistent with a 3cm pheochromocy-
toma with none of the adverse features associated with 
malignant potential. The patient recovered well post-op, 
his blood pressure normalised and he was discharged 
home well for follow-up at the Endocrine and Transplant 
clinics. Conclusion: We describe a rare case of a right 
adrenal pheochromocytoma in a young man with multiple 
co-morbidities, who completely recovered after tumor re-
section. This case highlights the crucial importance of 
investigating secondary causes of hypertension, espe-
cially in younger patients. This is the first documented 
case in the literature of a case of pheochromocytoma in a 
post-transplant patient with Cystic Fibrosis. References: 
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11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an 
NADPH-dependant reductase located in the sarcoplasmic 
reticulum (SR) lumen of skeletal muscle. It generates active 
glucocorticoids to regulate permissive and adaptive metab-
olism and contributes to the development of the Cushing’s 
syndrome phenotype in mice receiving oral corticosterone. 
The SR enzyme hexose-6-phosphate dehydrogenase 
(H6PDH) generates NADPH which supports 11β-HSD1 
activity. H6PDH depletion disrupts the SR NADPH/
NADP ratio leading 11β-HSD1 to assume glucocorticoid-
inactivating dehydrogenase activity. Little is understood 
regarding routes to NAD(P)(H) biosynthesis and me-
tabolism in the SR. Here we asked whether modulating 
cellular nicotinamide adenine dinucleotide (NAD+) avail-
ability (the parent molecule of NAD(P)(H)) would influence 
muscle 11β-HSD1 activity given its sensitivity to the SR 
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